BioTechMeditationScienceWellnessHealthcarePersonal Growth

The Brain on MDMA Can Go Somewhere CBT Has Never Been Able to Reach | Rachel Yehuda: Full Interview

Big Think
Big Think•Apr 10, 2026

Why It Matters

MDMA‑assisted therapy offers a breakthrough remission rate for PTSD, potentially transforming treatment standards and creating a sizable market for psychedelic‑based mental‑health solutions.

Key Takeaways

  • •Trauma persists long after events, unlike temporary stress responses.
  • •70% experience potentially traumatic events; only ~10% develop PTSD.
  • •Conventional CBT often fails due to overwhelming emotional distress.
  • •MDMA‑assisted therapy shows ~66% remission in phase trials.
  • •MDMA enables compassionate processing, enhancing therapy effectiveness significantly.

Summary

The interview with Dr. Rachel Yehuda explores why trauma endures far beyond the original event and how emerging psychedelic‑assisted treatments, especially MDMA, are reshaping PTSD care.

Yehuda distinguishes stress—typically resolved by removing the stressor—from trauma, which acts as a lifelong watershed. Roughly 70% of people worldwide encounter potentially traumatic events, yet only about 10% develop full‑blown PTSD, underscoring that individual response, not exposure alone, drives disorder onset. Conventional cognitive‑behavioral therapy often stalls because revisiting the memory can be unbearably distressing.

She cites phase‑2 and phase‑3 trials where two‑thirds of participants receiving MDMA‑assisted psychotherapy no longer met PTSD criteria, a remission rate far exceeding standard treatments. MDMA’s unique pharmacology creates a calm, empathetic state without ego dissolution, allowing patients to confront painful narratives with self‑compassion—examples include survivors of interpersonal violence and combat veterans re‑framing survival instincts as protective rather than shameful.

If FDA approval proceeds, MDMA‑assisted therapy could become a mainstream, reimbursable option, prompting new clinical protocols, training programs, and investment in psychedelic‑focused biotech firms. The shift promises faster recovery for millions, reduces long‑term healthcare costs, and challenges the mental‑health field to integrate pharmacological and psychotherapeutic modalities.

Original Description

Become a Big Think member to unlock expert classes, premium print issues, exclusive events and more: https://bigthink.com/membership/?utm_source=youtube&utm_medium=social&utm_campaign=yt_desc
Up next, The bizarre phenomena that medicine struggles to explain | David Linden: Full Interview ► https://www.youtube.com/watch?v=Hu1PyOP_NGA
Trauma doesn't end when the danger does, and for decades, science couldn’t explain why.
Rachel Yehuda, a leading PTSD researcher, has spent her career inside that question, uncovering how trauma leaves impressions on our genes, sometimes passing biological echoes on to the next generation.
Now, she’s focused on a therapy that could actually break the chain.
0:00 Introduction: What trauma does to the brain
0:20 Chapter 1: Why trauma sticks
3:05 Stress vs. trauma: what’s the difference?
5:55 Why most people don’t develop PTSD
8:37 Chapter 2: How MDMA-assisted therapy can break the loop
9:19 How trauma warps self-perception
12:40 MDMA-assisted therapy explained
16:38 How societal narratives shape recovery (or worsen it)
23:04 The reality of psychedelic therapy (not a quick fix)
28:55 Chapter 3: Healing can echo across generations
30:48 Epigenetics explained
40:00 Can healing be passed on too?
43:43 PTSD beyond fear: guilt, shame, and trauma
47:01 What real healing looks like
© Freethink Media Inc., All Rights Reserved.
----------------------------------------------------------------------------------
Go Deeper with Big Think:
►Become a Big Think Youtube Member
Get exclusive classes and early, ad-free access to new releases without leaving Youtube. https://www.youtube.com/@bigthink/membership/
►Become a Big Think Web Member
Get the entire Big Think Class library, premium print issues, live events, and more.
►Subscribe to Big Think on Substack
Get all of your favorite Big Think content delivered to your inbox.
►Listen to Big Think Interviews on Spotify
Insights from the world's biggest thinkers, now as a podcast
----------------------------------------------------------------------------------
About [Speaker Name]:
Rachel Yehuda, PhD, Professor of Psychiatry and Neuroscience, is the Director of the Traumatic Stress Studies Division at Icahn School of Medicine, and the Mental Health Patient Care Center Director at the James J. Peters Veterans Affairs Medical Center.
Dr. Yehuda has authored more than 300 published papers, chapters, and books in the field of traumatic stress and the neurobiology of PTSD. Her current interests include the study of novel treatments for PTSD, the examination of risk and resilience factors, the study of psychological and biological predictors of treatment response in PTSD, genetic, epigenetic, and molecular biological studies of PTSD and the intergenerational transmission of trauma and PTSD. Her team's research on cortisol and brain function has revolutionized our understanding and treatment of PTSD worldwide.
Dr. Yehuda has received many awards in recognition of her work including the Curt Richter Prize in Psychoneuroendocrinology, and the Laufer award from the International Society for Traumatic Stress. She was also awarded the Max Planck Institute for Psychiatry (Munich, Germany) 2004 Guest Professorship in Psychiatry and Neuroscience, and the Marcus Tausk Professorship in Leiden University to honor her accomplishments in the endocrinology of PTSD.
Dr. Yehuda received her PhD in Psychology and Neurochemistry and her MS in Biological Psychology from the University of Massachusetts at Amherst and completed her postdoctoral training in Biological Psychiatry in the Psychiatry Department at Yale Medical School.
She has an active federally funded clinical and research program that welcomes students and clinicians.

Comments

Want to join the conversation?

Loading comments...